XLO · Xilio Therapeutics, Inc.
$9.23
+0.00 (+0.00%)
At close · Aug 21
Market Cap
$53.37M
Shares
5.78M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| René Russo | Pharm.D. President and Chief Executive Officer | $6,451,495 |
| Christopher Frankenfield | Chief Financial and Operating Officer | $3,229,346 |
| Katarina Luptakova | Chief Medical Officer | $2,197,248 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| René Russo | Pharm.D. President and Chief Executive Officer | $1,454,729 |
| Christopher Frankenfield | Chief Financial and Operating Officer | $1,035,971 |
| Katarina Luptakova | Chief Medical Officer | $746,894 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Daniel Curran, M.D. | Class III director | Appointed | 2026-06-12 |
| Christina Rossi | director | Resigned | 2026-04-16 |
| Cheryl R. Blanchard, Ph.D. | Class III director | Appointed | 2026-04-16 |
| Paul Clancy | chair of the Board | Retired | 2026-01-08 |
| Sara M. Bonstein | chair of the Board | Appointed | 2026-01-08 |
| Akintunde Bello | Class II director | Appointed | 2025-06-10 |
| Aoife Brennan, M.D. | Class III director | Appointed | 2024-06-13 |
| James Shannon, M.D. | Class I director | Appointed | 2024-06-13 |
| Scott Coleman, Ph.D. | Chief Development Officer | Appointed | 2023-09-05 |
| René Russo, Pharm.D. | President | Appointed | 2023-09-05 |
| Katarina Luptakova, M.D. | Chief Medical Officer | Appointed | 2023-09-05 |
| Martin Huber, M.D. | President and Head of Research and Development | Resigned | 2023-09-05 |
| Christopher Frankenfield | Chief Operating Officer | Appointed | 2023-08-03 |
| Kevin Brennan | SVP, Finance and Accounting | Appointed | 2023-04-03 |
| Kevin Brennan | principal accounting officer | Appointed | 2023-04-03 |
| Kevin Brennan | Senior Vice President, Finance and Accounting, and appointed as the Company's principal financial officer and principal accounti | Appointed | 2023-04-03 |
| Edward C. English | vice president, finance, accounting and treasury and principal accounting officer | Resigned | 2022-12-23 |
| Tomas Heyman | Class I director | Appointed | 2022-09-15 |
| Salvatore Giovine | chief financial officer (principal financial officer) | Resigned | 2022-07-28 |
| Robert Ross, M.D. | Class II director of the Company | Appointed | 2022-06-16 |
| Martin Huber, M.D. | President of the Company | Appointed | 2022-06-16 |
| Rachel Humphrey, M.D. | board of directors | Resigned | 2022-02-04 |
| Yuan Xu, Ph.D. | Class II director | Appointed | 2022-01-06 |
Key facts
CIK
1840233
CUSIP
98422T209
13F (30d)
26 filings
26 filers
Visit website
Investor relations